However, a significant subset of breast cancers cannot be treated by these therapies because they do not express ERα or its surrogate predictive marker of response, the progesterone receptor (PR), and/or these cancers commonly show resistance to drugs that target the ERα pathway. This evidence concerns the gene ESR1 and breast cancer.